Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)

OBJECTIVES: Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. METHODS: A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Reginster, Jean-Yves, Dudler, Jean, Blicharski, Tomasz, Pavelka, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Annals of the Rheumatic Diseases 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561371/
https://www.ncbi.nlm.nih.gov/pubmed/28533290
http://dx.doi.org/10.1136/annrheumdis-2016-210860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561371/
https://www.ncbi.nlm.nih.gov/pubmed/28533290
http://dx.doi.org/10.1136/annrheumdis-2016-210860

Ejemplares similares